JWH-210
Synthetic cannabinoid
| JWH-210 | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 824959-81-1 |
| PubChem | 44418164 |
| DrugBank | |
| ChemSpider | 23249924 |
| KEGG | |
JWH-210 is a synthetic cannabinoid from the naphthoylindole family. It acts as a potent agonist of the CB1 receptor and CB2 receptor, with a slight preference for the CB2 receptor. JWH-210 is part of the JWH series of synthetic cannabinoids, which were developed by John W. Huffman in the 1990s for research purposes.
Chemical Structure
JWH-210 has the chemical formula C25H25NO. Its structure consists of a naphthalene ring substituted at the 1-position with an ethyl group and at the 4-position with a pentylindole group. The IUPAC name for JWH-210 is (4-ethylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone.
Pharmacology
JWH-210 is a potent agonist of the cannabinoid receptors, particularly the CB1 receptor and CB2 receptor. It has been found to have a higher affinity for the CB2 receptor compared to the CB1 receptor. This selectivity makes it of interest in research related to the endocannabinoid system and potential therapeutic applications.
Legal Status
JWH-210 is classified as a controlled substance in several countries. In the United States, it is listed as a Schedule I substance under the Controlled Substances Act. In the United Kingdom, it is classified as a Class B drug. Other countries, such as Canada and Germany, have also placed JWH-210 under their respective controlled substance regulations.
Research and Applications
JWH-210, like other synthetic cannabinoids, has been used in scientific research to study the endocannabinoid system and the effects of cannabinoid receptor activation. It has also been used in the development of new therapeutic agents targeting cannabinoid receptors. However, due to its potent effects and potential for abuse, its use is strictly regulated.
See Also
References
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
